0-9
A B C D E F G H I J K L M N O
P Q R S T U V W X Y Z
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found

HPV mRNA E6/E7

Test code(s) 90887

This is an outdated version of this FAQ. It was effective 02/28/2014 to 01/04/2016.

The current version is available here.

Question 1. Why order the HPV mRNA E6/E7 test instead of a high-risk HPV DNA test?

The HPV mRNA E6/E7 test uses the APTIMA® HPV mRNA method, which is shown to be more specific than an HPV DNA test.1,2 This can lead to fewer false-positive results and unnecessary invasive procedures such as colposcopy and biopsy.

The mRNA test determines the presence of E6/E7 mRNA from 14 high-risk HPV genotypes. HPV E6/E7 oncoproteins mediate the development of cervical cancer. Their overexpression, which can be measured as E6/E7 messenger RNA (mRNA) transcripts, is associated with a significantly increased risk of CIN and cervical cancer.3,4

Question 2. What is the current recommended use of high-risk HPV testing?

Current American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines recommend high-risk HPV testing for women aged 30-65 years as part of a cervical cancer screen. The HPV test is used in conjunction with cervical cytology (preferred screening method) every 5 years. Some women >65 years may need high-risk HPV testing too; please refer to the ASCCP Consensus Guidelines.5

ASCCP does not recommend routine high-risk HPV testing for women 21-29 years of age.5

Question 3. Can the HPV mRNA E6/E7 test be performed on anal/rectal specimens?

Yes. Quest Diagnostics Nichols Institute, San Juan Capistrano has validated the test for rectal swab specimens submitted in 3 mL liquid cytology (PreservCT®) vial. The test name is HPV mRNA E6/E7, Rectal, and the test code is 91932.

 
References
 
  1. APTIMA® HPV Assay [package insert]. San Diego, CA: Gen-Probe, Inc; 2011. http://gen-probe.com/pdfs/pi/502170-EN-RevA.pdf. Accessed December 3, 2013.
  2. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49:557-564.
  3. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65-70.
  4. Monsonegro J, Hudgens MG, Zerat L, et al. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Gynecol Oncol. 2012;125:175-180.
  5. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Cytology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542.
This FAQ is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

Document FAQS.129 Revision: 1